Views
4 years ago

25 - D Fadel, HA Serra - Abril 2004

  • Text
  • Aripiprazol
  • Receptores
  • Dosis
  • Receptor
  • Dopamina
  • Dopamine
  • Neuronas
  • Agonista
  • Aripiprazole
  • Antipsychotic
Farmacología del aripiprazol, un antipsicótico agonista parcial de la neurotransmisión dopaminérgica-serotonérgica

Referencias

Referencias bibliográficas 1) Adis R&D Profile: Aripiprazole (Abilitatâ), OPC 14597. Drugs R&D 2002;3:25-27. 2) Alexander G. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 1990;13(7):266-71. 3) Bandelow B, Meier A. Aripiprazole, a "dopamine-serotonin system stabilizer" in the treatment of psychosis. German J Psychiatry 2003;6(1): 9-16. 4) Breier A, Su T, Saunders R. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;10(suppl 3):21-28. 5) Burris K, Molski T, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-89. 6) Carlsson A. A Neurocircuitries and neurotransmitters interactions in schizophrenia. Int Clin Psychopharmacology 1995;10(Suppl 3):S21-S28. 7) Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and gaba in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001;293:2465-70. 8) Carlsson A. A paradigm shift in brain research. Science 2001;294(5544):1021-24. 9) Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1(3):179-86. 10) Carlsson A, Waters N, Carlsson M. Neurotransmitter interactions in schizophrenia. Therapeutic implications. Biol Psychiatry 1999; 46(10):1388-95. 11) Kuhn NJ. Learn lateral thinking first and specialize later. Nature 2000;404(6778):542. 12) Drugdex ® System in Micromedex ®: Aripiprazole. Healthcare Series for Windows ® Vol 119 in CD-ROM Micromedex (Thomson Healthcare), Greenwood Village, Colorado, USA. 2003. 13) Ferré S. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20(10):482-87. 1) Grace A. The tonic / phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 2000;95(suppl 2):S119-S28. 2) Grace A, Gerfen C. Catecholamines in the central nervous system. Adv Pharmacol 1998;42:655-70. 3) Gründer G, Carlsson A, Wong D. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003;60(10):974-77. 4) Holden C. Deconstructing Schizophrenia. Science 2003;299(5605):333-35. 5) Inoue A, Seto M, Sugita S, et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Mol Brain Res 1998;55(2):285-92. 6) Inoue T, Domae M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichloropheniyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC 14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Expt Ther 1996;277(1):137-43. 7) Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321(1):105-11. 8) Kapur S, Zipursky R, Remington G. Clinical and theoretical implications of 5HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93. 9) Kapur S, Zipursky R, Remington G, et al. 5HT2 and D2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998;155(7):921-28. 10) Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotic?: A new hypothesis. Am J Psychiatry 2001;158(3):360-69. 11) Keck P, Marcus R, Tourkodimitris S, et al. A Placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-58. 12) Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 2000;48(7):627-40. 13) Keltner N, Johnson V. Biological perspectives. Aripiprazole: A third generation of antipsychotic begins? Perspect Psychiatr Care 2002;38(4):157-59. 14) Kikuchi T, Tottori K. Uwahodo Y, et al. 7-{4-[4-(2,3-dichloropheniyl)-1-piperazinyl] butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC 14597), a New putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274(1):329-36. 15) Lahti A, Weiler M, Carlsson A, Tamminga C. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH 232 in schizophrenia. J Neural Transm 1998;105(6-7):719-34. 16) Lahti A, Weiler M, Corey P, et al. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-n-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998;43(1):2-11. 17) Lawler C, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (opc14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27. 18) McCarley RW, Salisbury DF, Hirayasu Y, et al. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first episode schizophrenia. Arch Gen Psychiatry 2002;59(4):321-31. 19) Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-contolled trials. Schizophr Res 2003;61(2-3):123-36. 20) Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology (Berl) 1999;146(2):139-43. 21) Momiyama T, Amano T, Todo N, Sasa M. Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area. Eur J Pharmacol 1996;310(1):1-8. 22) National PBM Drug Monograph: Aripiprazole (Abilifyâ) VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Revised February 2003. 23) Nakai S, Hirose T, Uwahodo Y, et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 2003;472(1-2):89-97. 24) Oshiro Y, Sato S, Kurahashi N, et al: Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-{4-[4-(2,3-dichloropheniyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2 (1H)-quinolinone derivatives. J Med Chem 1998;41(5):658-67. 25) Paladini CA, Fiorillo CD, Morikawa H, Williams JT. Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons. Nat Neurosci 2001;4(3):275-81. 26) Poole R. Aripiprazole: A novel antipsychotic may lessen risk of metabolic disorders. Inpharma 2003;1400:18-20. 27) Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonist as new a agents for the treatment of Parkinson`s disease. Trends Pharmacol Sci 1997;18(9):338-44. 28) Sonesson C, Lin CH, Hansson L, et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 1994;37(17):2735-53. 29) Sugiyama A, Satoh Y, Hashimoto K: In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC 14597) to haloperidol. Toxicol Appl Pharmacol 2001;173(2):120-28. 30) Trichard C, Paillere-Martinot ML, Attar-Levy D, et al. Binding of antipsychotic drugs to cortical 5HT2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998;155(4):505-8. 31) Vanderschuren LJ, Schmidt ED, De Vries TJ, et al. A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine and neurochemical sensitization in rats. J Neurosci 1999;19(21):9579-86. 32) Walters J JR, Ruskin DN, Allers KA, Bergstrom DA. Pre and postsynaptic aspects of dopamine-mediated transmission. Trends Neurosci 2000;23(suppl):S4-S47 33) Winans E. Aripiprazole. Am J Health Syst Pharm 2003;60(23):2437-45. 34) Wood JN, Grafman J. Human prefrontal cortex: Processing and representational perspectives. Nat Rev Neurosci 2003;4(2):139-46. 35) Yamada S, Harano M, Yokoo H, Tanaka M. Antagonistic effects of OPC 14597, a novel antipsychotic drug, on quinpirole- and (-) -sulpiride-induced changes in evoked dopamine release in rat striatal slices. J Pharm Pharmacol 1997;49(2):206-8. 49) Yokoi F, Gründer G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC14597): A study using positron emission tomography and [11 C] raclopride. Neuropsychopharmacology 2002;27(2):248-59.

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015